In recent years, different RLT radiopharmaceuticals exploiting PSMA-targeting radioligands have been developed, among which the novel theragnostic 177Lu-PSMA-617 [5] is considered to be one of the most promising, with high specificity for the tumor and moderate uptake in the whole body and organs at risk (OaR). Here, FOLH1 is linked to neoplasm.